RBC Capital Maintains Outperform on Teladoc Health, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge maintains an 'Outperform' rating on Teladoc Health (NYSE:TDOC), but has lowered the price target from $35 to $30.

October 25, 2023 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Teladoc Health's price target has been lowered from $35 to $30 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company, which could balance out the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100